NVCR News and Press, NovoCure Limited From 10/12/21

Aggressive forms of cancer can be devastating to patients and their families. This kind of diagnosis brings uncertainties about the quality of life and the length of time a patient has left. Healthcare company Novocure (NASDAQ: NVCR) aims to improve both these aspects for patien...

Margetuximab, a monoclonal antibody for HER2+ breast cancer under development from Zai Lab (NASDAQ:ZLAB), met its primary endpoint in a phase 2 study in previously treated patients in China. The primary endpoint was median progression-free survival. The hazard ratio for progression-free survi...

Zai Lab (NASDAQ:ZLAB) and Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in the phase 2 pilot trial evaluating the safety and efficacy of Tumor Treating Fields ((TTFields)) in combination with chemotherapy as a first-line treatment in patients with gastric aden...

Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology com...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the t...

Final data collection is expected in the first half of 2022 Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmac...

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenoc...

NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields. Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards. The healthcare equipment play is investing heavily ...

Novocure (NASDAQ: NVCR) is the producer of a cancer-fighting wearable device called Optune. Its tumor-treating technology uses low-power electrical fields to interfere with a cancer cell's ability to multiply. The stock skyrocketed 40% in a single day back in April on positive n...

NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has grant...